{"schema_version":"1","generated_at":"2026-11-21T07:31:11.993Z","data_as_of":null,"url":"https://www.findmykol.com/kol/fredrick-wigley","json_url":"https://www.findmykol.com/kol/fredrick-wigley/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"fredrick-wigley","name":"Fredrick Wigley","credential":"MD","specialty":"Rheumatology","specialty_raw":"Rheumatology","therapeutic_area":"Rheumatology/Immunology","therapeutic_areas":["Rheumatology/Immunology"],"institution":"Johns Hopkins University","institution_url":"https://www.findmykol.com/institution/johns-hopkins-university-school-of-medicine","city":"Baltimore","state":"MD","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Fredrick Wigley is a Rheumatology/Immunology physician affiliated with Johns Hopkins University. OpenAlex indexes 340 publications with 25,420 citations (h-index 85); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Rheumatology profiles in the FindMyKOL directory.","overview":null,"focus":{"indications":[],"research_topics":["Rheumatology/Immunology"]},"scholarship":{"works_count":340,"cited_by_count":25420,"h_index":85,"latest_activity_year":2023,"citation_standing":{"top_percent":10,"cohort":"Rheumatology","method":"https://www.findmykol.com/about#citation-standing"},"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00501995","title":"High Dose Cyclophosphamide for Treatment of Scleroderma","phase":"PHASE3","status":"COMPLETED","role":"Overall official","sponsor":"Johns Hopkins University","source_url":"https://clinicaltrials.gov/study/NCT00501995","trial_url":"https://www.findmykol.com/trial/NCT00501995"},{"nct":"NCT00498615","title":"A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon","phase":"PHASE3","status":"COMPLETED","role":"Overall official","sponsor":"Johns Hopkins University","source_url":"https://clinicaltrials.gov/study/NCT00498615","trial_url":"https://www.findmykol.com/trial/NCT00498615"}],"source":"trials"},"prescribing":{"data_year":2023,"areas_total":9,"areas_shown":3,"areas":[{"area":"Cardiovascular","share_pct":36.2,"classes_total":10,"classes":[{"class":"Calcium channel blocker","setting":"prescribed","share_pct":17.2,"drugs":[{"name":"Amlodipine Besylate","share_pct":82.4},{"name":"Nifedipine Er","share_pct":17.6}],"max_beneficiaries":null},{"class":"Angiotensin receptor blocker (ARB)","setting":"prescribed","share_pct":3.8,"drugs":[{"name":"Losartan Potassium","share_pct":100}],"max_beneficiaries":13}]},{"area":"Metabolism & gastrointestinal","share_pct":26.8,"classes_total":4,"classes":[{"class":"Proton pump inhibitor","setting":"prescribed","share_pct":13.5,"drugs":[{"name":"Omeprazole","share_pct":45.5},{"name":"Pantoprazole Sodium","share_pct":36.4},{"name":"Esomeprazole Magnesium","share_pct":18.2}],"max_beneficiaries":null},{"class":"H2 blocker","setting":"prescribed","share_pct":8.9,"drugs":[{"name":"Famotidine","share_pct":100}],"max_beneficiaries":34}]},{"area":"Nervous system","share_pct":20.7,"classes_total":6,"classes":[{"class":"SSRI","setting":"prescribed","share_pct":5.2,"drugs":[{"name":"Sertraline Hcl","share_pct":58.2},{"name":"Trazodone Hcl","share_pct":21.8},{"name":"Paroxetine Hcl","share_pct":20}],"max_beneficiaries":null},{"class":"Gabapentinoids","setting":"prescribed","share_pct":4.7,"drugs":[{"name":"Gabapentin","share_pct":100}],"max_beneficiaries":18}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":5,"fiscal_years":{"first":1992,"last":2016},"rows_total":23,"shown":3,"withheld":20,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"T32AR048522","title":"Multidisciplinary Rheumatology Training Program","fiscal_year":2016,"amount_usd":"292175","organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/T32AR048522"},{"project":"T32AR048522","title":"Multidisciplinary Rheumatology Training Program","fiscal_year":2015,"amount_usd":"256767","organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/T32AR048522"},{"project":"T32AR048522","title":"Multidisciplinary Rheumatology Training Program","fiscal_year":2014,"amount_usd":"292903","organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/T32AR048522"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline","year":2023,"journal":"American Journal of Respiratory and Critical Care Medicine","source_url":"https://doi.org/10.1164/rccm.202306-1113st","status":"verified"},{"title":"Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis–Associated Versus Idiopathic Pulmonary Arterial Hypertension","year":2018,"journal":"Circulation","source_url":"https://doi.org/10.1161/circulationaha.117.033147","status":"verified"},{"title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","year":2016,"journal":"The Lancet Respiratory Medicine","source_url":"https://doi.org/10.1016/s2213-2600(16)30152-7","status":"verified"},{"title":"Raynaud’s Phenomenon","year":2016,"journal":"New England Journal of Medicine","source_url":"https://doi.org/10.1056/nejmra1507638","status":"verified"},{"title":"Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension","year":2016,"journal":"Circulation","source_url":"https://doi.org/10.1161/circulationaha.116.022082","status":"verified"}],"source":"works"},"similar":[{"name":"Daniel Laheru","slug":"daniel-laheru","institution":"Johns Hopkins University","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/daniel-laheru","json_url":"https://www.findmykol.com/kol/daniel-laheru/profile.json"},{"name":"Clifton Bingham","slug":"clifton-bingham","institution":"Johns Hopkins University","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/clifton-bingham","json_url":"https://www.findmykol.com/kol/clifton-bingham/profile.json"},{"name":"Demosthenes G. Katritsis","slug":"demosthenes-katritsis","institution":"Johns Hopkins University","url":"https://www.findmykol.com/kol/demosthenes-katritsis","json_url":"https://www.findmykol.com/kol/demosthenes-katritsis/profile.json"},{"name":"Tanguy Seiwert","slug":"tanguy-seiwert","institution":"Johns Hopkins University","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/tanguy-seiwert","json_url":"https://www.findmykol.com/kol/tanguy-seiwert/profile.json"},{"name":"David Felson","slug":"david-felson","institution":"Boston University","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/david-felson","json_url":"https://www.findmykol.com/kol/david-felson/profile.json"},{"name":"Marc Hochberg","slug":"marc-hochberg","institution":"University of Maryland School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/marc-hochberg","json_url":"https://www.findmykol.com/kol/marc-hochberg/profile.json"},{"name":"Philip Mease","slug":"philip-mease","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/philip-mease","json_url":"https://www.findmykol.com/kol/philip-mease/profile.json"},{"name":"Michelle Petri","slug":"michelle-petri","institution":"Johns Hopkins University School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/michelle-petri","json_url":"https://www.findmykol.com/kol/michelle-petri/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"funding":20,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}